|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02633 JACOBSON PHARMA
Nominal 
1.010 +0.010 (+1.000%) | 2024/09 - Interim HKD(K$) | %Chg (Compare to Interim) | 2024/03 HKD(K$) | 2023/03 HKD(K$) | 2022/03 HKD(K$) | 2021/03 HKD(K$) | |
| Turnover | 810,002 | 13.300% | 1,467,798 | 1,785,579 | 1,595,543 | 1,445,915 |
| Cost of Sales | (458,531) | 10.799% | (847,323) | (1,038,407) | (975,021) | (884,832) |
| Gross Profit | 351,471 | 16.737% | 620,475 | 747,172 | 620,522 | 561,083 |
| 2024/09 - Interim HKD(K$) | %Chg (Compare to Interim) | 2024/03 HKD(K$) | 2023/03 HKD(K$) | 2022/03 HKD(K$) | 2021/03 HKD(K$) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 129 | -61.145% | 165 | (3,560) | (3,768) | (5,527) | |
| Profit / (Loss) before Taxation | 175,377 | 47.549% | 254,583 | 339,755 | 231,433 | 220,569 | |
| Taxation | (35,087) | 62.598% | (44,414) | (56,546) | (43,728) | (34,264) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | 52,392 | -- | -- | 3 | |
| Non-controlling Interests | 0 | -- | (23,810) | (32,165) | (10,039) | (12,595) | |
| Others | -- | -- | 28,217 | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 140,290 | -8.926% | 266,968 | 251,044 | 177,666 | 173,713 | |
| 2024/09 - Interim HKD(K$) | %Chg (Compare to Interim) | 2024/03 HKD(K$) | 2023/03 HKD(K$) | 2022/03 HKD(K$) | 2021/03 HKD(K$) | |
| Net Finance Costs / (Income) | 13,626 | -56.757% | 54,702 | 49,298 | 23,798 | 28,056 |
| Depreciation & Amortisation | 71,464 | 0.085% | 141,823 | 184,460 | 192,597 | 191,701 |
| Directors' Emoluments | -- | -- | 31,653 | 27,148 | 10,886 | 9,634 |
| 2024/09 - Interim | %Chg (Compare to Interim) | 2024/03 | 2023/03 | 2022/03 | 2021/03 | |
| Auditor's Opinion Status | N/A | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2024/09 - Interim | %Chg (Compare to Interim) | 2024/03 | 2023/03 | 2022/03 | 2021/03 | |
| EPS (cts) | 7.070 | -12.283% | 13.900 | 13.130 | 9.270 | 9.070 |
| DPS (cts) | 3.500 | -- | 5.500 | 5.180 | 3.880 | 2.300 |
| Dividend Payout Ratio (%) | 49.505% | -- | 39.568% | 39.452% | 41.855% | 25.358% |
| Cash flow per share ($) | -- | -- | 0.252 | 0.330 | 0.212 | 0.214 |
| NBV per share ($) | 1.216 | -- | 1.186 | 1.415 | 1.288 | 1.236 |
| Remarks: | Real time quote last updated: 20/12/2024 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders ($) | HKD 140,290,000 |
| %Change | -8.926% |
| EPS / (LPS) | HKD 0.071 |
| NBV Per Share ($) | HKD 1.216 |